Related Experiment Video
Updated: Mar 21, 2026

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
Published on: March 28, 2025
Epidemiology and Outcomes of Hospitalizations for Children with Encephalopathy Associated with Severe Liver
Lilia Christner1, Achamyeleh Gebremariam1,2, Folafoluwa Odetola1,2,3
1Department of Pediatrics, University of Michigan, Ann Arbor, MI.
Insights
Nearly half of children hospitalized for severe liver dysfunction-associated encephalopathy die. Patient factors like comorbidities and multiple organ dysfunction (MOD) impact mortality, not hospital characteristics. Individualized, age-specific care is crucial.
Area of Science:
- Pediatric critical care medicine
- Hepatology
- Public health
Background:
- Severe liver dysfunction-associated encephalopathy (SLD-AE) poses a significant mortality risk in children.
- Understanding patient- and hospital-level factors is crucial for improving outcomes.
Purpose of the Study:
- To identify independent patient- and hospital-level factors associated with mortality in pediatric SLD-AE.
Main Methods:
- Retrospective analysis of US hospitalizations (2016, 2019, 2022) using the Kids' Inpatient Database.
- Multivariable logistic regression models were used to assess mortality predictors.
Main Results:
- Of 3378 hospitalizations, 45% resulted in in-hospital mortality.
- Mortality was associated with patient factors: age, multiple organ dysfunction (MOD), and comorbidities.
- No significant association was found between mortality and hospital characteristics.
Conclusions:
- High mortality (45%) in pediatric SLD-AE highlights an urgent need for intervention.
- Individualized, age-specific management strategies focusing on MOD and comorbidities are essential.
- No regional or hospital-level variations in mortality were observed.
Objective:
To determine patient-level and hospital-level factors independently associated with mortality in pediatric severe liver dysfunction-associated encephalopathy.
Study Design:
This was retrospective analysis of hospitalizations of children 0-20 years old with severe liver dysfunction-associated encephalopathy in the US, using combined administrative data from the 2016, 2019, and 2022 versions of the Kids' Inpatient Database. National estimates of hospitalizations were generated, and multivariable logistic regression models were constructed to determine patient and hospital characteristics independently associated with mortality.
Results:
Of an estimated 3378 hospitalizations nationally, 94% were to urban teaching hospitals, 67% were of children >5 years, and 56% were of male patients. Comorbidities and multiple organ dysfunction (MOD) were present in 93% and 97% of hospitalizations, respectively. In-hospital mortality was 45%, with average hospital stay of 22 days, and average hospital charge of $622 069 (2022 US dollars). In-hospital mortality was associated with patient characteristics including age, MOD, and the presence of comorbidities, but not hospital characteristics. In comparison with infants, hospitalization of older children was associated with lower odds of mortality. Independent association with greater odds of mortality was observed for each nonhepatic organ dysfunction (OR 1.50; 95% CI 1.38-1.64), and the presence of comorbidities (OR 4.10; 95% CI 2.75-6.13).
Conclusions:
Nearly 1 in 2 hospitalizations for pediatric severe liver dysfunction-associated encephalopathy ended in death. Hospitalizations occurred predominantly at urban hospitals, with no regional or hospital variation in mortality. Efforts to mitigate mortality need to be individualized and age-specific, with emphasis on preventing or alleviating MOD.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

